Scholarlink

<p>Non-small cell lung cancer (NSCLC) remains a formidable global health challenge, with heterogeneous molecular characteristics influencing prognosis and treatment response. We present a novel computational framework named ASTUTE (<Emphasis Type="Underline">A</Emphasis>ssociation of <Emphasis Type="Underline">S</Emphasis>oma<Emphasis Type="Underline">T</Emphasis>ic m<Emphasis Type="Underline">U</Emphasis>ta<Emphasis Type="Underline">T</Emphasis>ions to gene <Emphasis Type="Underline">E</Emphasis>xpression profiles), designed to perform genotype-phenotype mapping through the integration of genomic and transcriptomic data. Through the systematic analysis of over 3600 samples from diverse NSCLC datasets and multiple cancer types, we uncovered intricate associations between <i>KEAP1</i>/<i>NFE2L2</i> mutations and the NRF2 pathway activation. Our study identified novel NRF2-related functionalities associated with specific genetic alterations and revealed a <i>KEAP1</i>/<i>NFE2L2</i> expression signature predictive of prognosis across different cancer types. These findings enhance our understanding of cancer pathogenesis and drug resistance mechanisms mediated by NRF2 activation, paving the way for tailored therapeutic interventions and the development of prognostic biomarkers. Our approach exemplifies the power of integrating genomic and transcriptomic data to elucidate cancer mechanisms, thereby advancing the field of precision oncology.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrative analysis of KEAP1/NFE2L2 alterations across 3600+ tumors reveals an NRF2 expression signature as a prognostic biomarker in cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月18日

查看全文
  • Valentina Crippa,
  • Nicoletta Cordani,
  • Alberto Maria Villa,
  • Federica Malighetti,
  • Matteo Villa,
  • Luca Sala,
  • Andrea Aroldi,
  • Rocco Piazza,
  • Diego Cortinovis,
  • Luca Mologni,
  • Daniele Ramazzotti

摘要

Non-small cell lung cancer (NSCLC) remains a formidable global health challenge, with heterogeneous molecular characteristics influencing prognosis and treatment response. We present a novel computational framework named ASTUTE (Association of SomaTic mUtaTions to gene Expression profiles), designed to perform genotype-phenotype mapping through the integration of genomic and transcriptomic data. Through the systematic analysis of over 3600 samples from diverse NSCLC datasets and multiple cancer types, we uncovered intricate associations between KEAP1/NFE2L2 mutations and the NRF2 pathway activation. Our study identified novel NRF2-related functionalities associated with specific genetic alterations and revealed a KEAP1/NFE2L2 expression signature predictive of prognosis across different cancer types. These findings enhance our understanding of cancer pathogenesis and drug resistance mechanisms mediated by NRF2 activation, paving the way for tailored therapeutic interventions and the development of prognostic biomarkers. Our approach exemplifies the power of integrating genomic and transcriptomic data to elucidate cancer mechanisms, thereby advancing the field of precision oncology.